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Overcoming platinum drug resistance represents a major clinical challenge in osteosarcoma (OS) treatment. The high rates and patterns of therapeutic failure seen in patients are consistent with a steady accumulation of drug-resistant cancer stem cells (CSCs). Notch signaling is implicated in regulating CSCs and tumor resistance to platinum. Thus, we attempt to investigate whether inhibiting of Notch pathway could sensitize cisplatin (CDDP) to CDDP-resistant OS cells and the underlying molecular mechanisms. OS cell lines resistant to CDDP were treated with DAPT, CDDP or combination, we present evidences that DAPT enhances the cytotoxic effect of CDDP in resistant OS by inhibiting proliferation, resulting in G0/G1 cell-cycle arrest, inducing apoptosis, and reducing motility. In addition, DAPT targeting depletes OS stem cells (OSCs), thus increasing tumor sensitivity to platinum, which indicating that a dual combination targeting both OSCs and the bulk of tumor cells are needed for tumor eradication. We also found that the combination of CDDP and DAPT exhibit additive suppression on phosphorylated AKT and ERK, contributing to the anticancer effects. In animal model, this combination therapy inhibits the growth and metastasis of CDDP resistant tumor xenografts in nude mice to a greater extent than treatment with either reagent alone. Based on these results, we conclude that CDDP plus DAPT was able to sensitize CDDP-resistant human OS cells to CDDP by downregulation of Notch signaling. CDDP and DAPT combination treatment may be effective and promising for advanced OS.
| INTRODUCTION
Osteogenic sarcoma, also referred to osteosarcoma (OS), is the most common primary malignant bone tumor. OS affects patients of all ages but shows a substantially higher incidence in children and early adulthood, which is the leading cause of disabling for childhood and adolescence, platinum compounds-based therapies are the current global standard for neoadjuvant chemotherapy. 1, 2 The platinum-based anticancer drugs, including cisplatin (CDDP) (Supplementary Figure S1A) , carboplatin and oxaliplatin, are currently among the most potent and widely used chemotherapeutic agents in clinical. They are also used for treating a variety of soild cancers, such as breast, ovarian, cervical, testicular, colorectal, bladder, non-small-cell lung, and head and neck cancers. 3, 4 As the leading anticancer drug, CDDP has been used for nearly four decades in standard chemotherapy regimens. 2 The effect of platinum-based anticancer chemotherapy is positively with dose, but high doses of CDDP are accompanied by severe side effects as manifested by renal impairment, ototoxicity, neurotoxicity, and vomiting on the patients during the treatment. 5 In addition, prolonged usage of CDDP in chemotherapy also induces drug resistance from intrinsic and acquired via multiple mechanisms. 6 Platinum resistance is the single most important factor after stage in determining prognosis. Development of CDDP resistance is often associated with multidrug resistant phenotype, including cancer stem cells (CSCs) and disorder of signaling pathway. 7, 8 It has been postulated that within a tumor, a minor subpopulation of cells, named
CSCs, drive the self-renewal and differentiation that account for the initiation, metastasis, proliferation, therapeutic resistance, and recurrence of cancer. Recently, studies have also presented that CSCs may be involved in the mechanisms of multidrug resistance. 9, 10 OS stem cells (OSCs) can also evade senescence and apoptosis through the Notch pathway to resist toxicity of chemotherapy.
11
Notch signaling is one of the most important signaling cascades involved in drug resistance in tumor cells. 12 A previous study demonstrated that activation of the Notch signaling was linked to chemoresistance of urothelial carcinoma to CDDP 13 and inhibition of Notch signaling with gamma-secretase inhibitors (GSIs) could target the leukemia-initiating cells, sensitize acute myeloid leukemia to chemotherapy, and be synergistic with some antineoplastic agents. 14 Notch genes encode transmembrane receptors that are highly conserved from invertebrates to mammals. These receptors interact with ligands expressed by adjacent cells to regulate cell fate specification, proliferation, differentiation, and survival. 15 The Notch system in vertebrates is comprised of four receptors (Notch1-4) and at least five ligands from the families Delta/Serrate/LAG-2 (DSL): Deltalike (Dll)-1, Dll-3, Dll-4, Jagged-1, and Jagged-2. 15 In ovarian cancer patients who received CDDP treatment, the activity of Notch signaling in tumor tissue correlates with drug resistance and poor prognosis. 16 Also, in a mouse model, the actived Notch pathway promotes acquired resistance to CDDP in serially passaged OS xenografts. 8 and 143B were established by serial desensitization of these three cell lines for 9 months and partly according previous studies, 8, 12, 20 and these resistant OS cell lines are named U2OS/R, MG63/R, and 143B/R , respectively. In parallel, parental U2OS, MG-63 and 143B cells were exposed to DMSO (vehicle solution) in the same dose-escalation manner. Generation of parental cells and resistant OS cells and growth conditions were described previously. 8 
| Cell viability
Cell viability was assessed as described previously. 8 
| Synergy analysis
The synergistic effect of CDDP and DAPT was determined based on the combination index (CI) using CalcuSyn, version 2.1 (Biosoft®). The CI indicated synergism at less than 1.0, antagonism at greater than 1.0, and an additive effect at 1.0. 21 
| Reverse transcription quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-RCR) was done according standard techniques, as described previously. 22 The gene specific primers used are listed in Supplementary Table S1 .
| Western-blot analysis
For western blot analysis, proteins were extracted with Protein Lysis Buffer (Roche, Rotkreuz, Switzerland). And detail protocol for western blotting is described previously 8 and manufacturer's instructions.
| Animal experiment
To determine the tumorigenicity of resistant model in vivo, 4-week-old male BALB/c-nu/nu nude mice were obtained from Center for Animal Experiment of Wuhan University and housed in laminar flow cabinets under specific pathogen-free conditions with food and water ad libitum.
The study protocol was approved by the Experimental Animal Care 
| Statistics
Statistical analyses were performed using the SPSS 16.0 statistical software package. P value was calculated using chi-square in contingency Figures 1C and 1D ). The mRNA levels of Notch target genes (Hes1, Hes5, and HeyL) also elevated in tumor samples compared with ANTTs ( Figure 1E ). It is noteworthy that the whether NICD1 protein expression levels or Notch downstream target genes mRNA transcription levels exhibit features that their were higher in chemotherapyresistant group than in chemotherapy-sensitive group ( Figure 1A -E).
These results indicate that NICD1 is upregulated in OS tissues and plays an important role in OS tumorigenesis and chemoresistance. In view of the fact that tumor resistance to chemotherapy is closely related to stem cell-like properties, 25, 26 we examined the expression of Figure S2A and Table S2 ). The expression of MDR1
(multi-drug resistance gene1) and its corresponding expression protein P-gp (P-glycoprotein) in resistant OS were significantly increased, which fully demonstrated the generation of drug resistance. 24 The resistance index of these three resistant OS cell lines increased by 2.56-, 2.03-, and 2.26-folds, respectively, according to the 24 h IC50 (half-inhibitory concentration) ( Figure 2C and Supplementary Figure S2A and Table S2 ). Table S3 ). Our results showed that the growth-inhibitory effects of CDDP and DAPT is different in U2OS/R, MG63/R, and 143B/R cells whereas all are in the vicinity of 16 and 40 µM, respectively. Both CDDP and DAPT are used in a concentrationas well as time-dependent manner to perform an anticancer effect.
| DAPT synergistically increased CDDP-mediated cytotoxicity in resistant OS
The treatment of OS with CDDP is linked with its concentrationlimiting toxicity. 25 Therefore, we aimed to improve the cytotoxic
efficacy of CDDP by reducing its concentration in presence of DAPT. Table S4 ).
| Enhanced cell cycle arrest by combination of CDDP and DAPT in resistant OS cells
To elucidate the mechanisms involved in CDDP or DAPT mediated cell proliferation inhibition, we detected and analyzed cell cycle distribu- Figure 4E ). In additional, ELISA assay showed that combination-treated could lead to a decrease in the levels of VEGF secreted in the culture medium ( Figure   4F ). All these data indicated that combined application of CDDP and DAPT could effectively inhibited the expression and activities of VEGF, MMP-2, and MMP-9 in resistant OS cells compared to the monotherapy groups and control group.
| Inhibition of Notch signaling pathway decreases the CSCs phenotype in resistant OS cells
We have confirmed that CDDP-resistant OS cells could enrich CSCs previously. 8 And in this study we also showed that the expression of 
| CDDP combined with DAPT inhibits Notch signaling, p-AKT, and p-ERK activation
As the combination of CDDP and DAPT showed the greater inhibition of cell proliferation, induction apoptosis and reduction mobility as synthetic way, insight was gained with regard to the mechanisms.
FIGURE 4
Combination of CDDP and DAPT decreased more cell motility. A, Cell migration was determined by wound-healing assay following treatment with CDDP and DAPT alone or in combination. B, The relative wound distance of migration was calculated as shown in (A). C, Invasion assay showing the number of cells that had passed through the Matrigel™-precoated filters. The cell counts presented are the mean values/field from at least five randomly selected low-power fields from three independent experiments. D, Western blotting analysis of VEGF, MMP-2, and MMP-9 proteins expression following treatment with CDDP and DAPT alone or in combination. GAPDH was used as an internal control. E, Gelatin zymography analysis the activities of MMP-2 and MMP-9 of resistant OS cells after 24 h treatment. F, ELISA assay were performed to detect the VEGF secreted of resistant OS cells after 24 h treatment. Data were expressed as mean ± SD from at least three independent experiments. NS, not significant. *P < 0.05, **P < 0.01,***P < 0.001 Figure 6E . In addition, tumor metastasis were found in the lungs according to the HE staining sections ( Figure 6F ), and we found that combined CDDP and DAPT compared to the vehicle and either agent alone, regardless of the number or volume of metastases were significantly less or smaller ( Figures 6F and 6G ).
In addition, apoptosis related mRNA and protein levels were detected from xenografts mice of tumor sections. We tested the expressions of Bax, Bcl-2, Caspase-3, and Caspase-9, respectively.
qRT-PCR analysis demonstrated alterations in the levels of expression of Bax (proapoptotic) and Bcl-2 (antiapoptotic), resulting in a significant increase in Bax after treatment of the resistant xenografts with CDDP plus DAPT, and the Bcl-2 shown opposite result ( Figure 6H ). The relative mRNA expression of Caspase-3 and Caspase-9 of mice tumor tissues were highest in CDDP + DAPT group followed by CDDP alone, DAPT alone, and vehicle in that order ( Figure 6H ). Subsequently, Western blotting were performed and the results were similar to qRT-PCR as shown in Figure 6I . We also examined expression levels of NICD1, p-AKT, p-ERK, and TUNEL in sectioned mice tumors after CDDP and DAPT alone or in combination administration ( Figure 6K ). TUNEL expression significantly increased in combination treatment, whereas NICD1 expression decreased by ≈45% ( Figure 6L ). In addition, combination treatment resulted in significant downregulation of p-AKT and p-ERK compared to the control group ( Figures 6K and 6L ). However, both the expression p-AKT and p-ERK decreased in the CDDP treatment group, which indicated that CDDP could inhibit the activities of PI3K/AKT and MAPK signaling pathway ( Figures 6K and 6L ).
To further confirm the results mentioned above, Notch, PI3K/ AKT, and MAPK signaling pathway in resistant xenografts mice tumor tissues were analysis. Consistent with the in vitro and above data, there was a reduction of NICD1, p-AKT, and p-ERK proteina levels after combined treatment compared with the vehicle (Figures 6M and   6N ). Thus, all these results indicated that CDDP in combination with DAPT treatment could markedly inhibit 143B chemoresistant xenograft growth in vivo and improves nude mice survival.
| DISCUSSION
Chemotherapy resistance of OS is a difficult problem in clinical. Herein we demonstrate that Notch signaling plays a key role for OS stem cell maintain and underlies mechanism for resistance to chemotherapy.
We present evidence of human specimen that Notch signaling is much greater in the chemoresistance OS and drives a CSCs phenotype. We
demonstrate that Notch pathway is critical for these OSCs and thus targeting the Notch signaling pathway may be an effective therapeutic strategy.
Defects in apoptosis are common phenomena in many types of cancer as well as critical steps in tumorigenesis and resistance to therapy. Thus, traditional cancer therapy mainly targets the cell apoptosis machinery or enhances apoptosis. 30 CDDP is a platinum based, alkylating-like drug that crosslinks DNA to induce apoptosis. It is used to treat many types of solid cancer, such as ovary, testicular, bladder, lung, head and neck, thoracic, and colorectal cancers. 3, 4 Although CDDP has potent antitumor effects in various cancer models, it is limited in clinical practice due to its toxicities and intrinsic or acquired drug resistance. 25, 31 Many research teams have attempted to find ways to improve its efficacy and reduce its toxicity, such as FIGURE 6 Continued.
changing its structure or assessing combination therapy with other drugs. 4 Researches have shown that combination therapy based on the synergistic effect between drugs owning multiple drug targets has been used to overcome drug resistance. 16, 19, 32, 33 Recently many research groups have reported synergistic anticancer effects of treatment with a combination of a drug and a signaling pathway inhibitor in vitro and in vivo cancer models. 34, 35 Liu et al 34 other scholars studies. 37 We also found that DAPT promoted G0/ G1-phase arrest via reduction of Cyclin D1, Cyclin E1, CDK2, SKP2, c-Myc and increase p21, which were consistent with the findings of other earlier studies showed that DAPT induces G0/G1-phase arrest in human OS cells and other tumors. 38, 39 It is not surprising that the G0/G1-phase arrest induced by CDDP and DAPT combination treatment was significantly greater than monotherapy group. Cyclin D, cyclin E, and pRb have been reported to promote G0/G1-S phase progression. 40 In addition, SKP2 has been reported to be a component of ubiquitin E3 ligase complex which regulats G0/G1-S transition by degradation of the CDK inhibitors p21. 41 p21 can bind to various CDKs, including Cyclin D/CDK4, Cyclin E/CDK2, and Cyclin A, and inhibit their kinase activity. 42 Thus, CDDP and DAPT combination treatment significantly inhibited U2OS/R, MG63/R and 143B/R cells proliferation, which was partially related to cell cycle arrest.
CDDP induces apoptosis via various proteins, likely through the extrinsic death receptor pathway or the intrinsic mitochondrial pathway.
Resistance to CDDP might develop through decreased expression or loss of pro-apoptotic factors, or through increased expression of antiapoptotic proteins. 4 Generally apoptosis is mediated by caspase activation, an event that is tightly regulated and involves two major pathways (the intrinsic and extrinsic pathways). The release of mitochondrial cytochrome c represents the main event for the intrinsic and the extrinsic pathways. 43 tendency to lung and used by many scholars working on the same field.
In this study, with primary tumor resected at the end of the experimental design, all mice in vehicle group presented 100% lung metastasis, confirming the model to be ideal in studying tumor with lung metastasis.
Whereas the combined treatment group of lung metastases are not only the smallest in volume but also the least in number, this result is consistent with the in vitro study. It might account for the underlying mechanism for the synergistic repression of primiary OS and reduce metastatic potential by the combination of CDDP and DAPT.
We found that CDDP plus DAPT treatment significantly suppressed resistant OS cell growth and mobility that it is accompanied by restraining Notch signaling. The cytotoxic effect of CDDP plus DAPT seemed to be caused by cell cycle arrest and consequent apoptotic cell death and reduced the proteins related to invasion and metastasis. We ERK is a major effect target of the mitogen-activated protein kinase (MAPK) pathway, and the MEK/ERK signaling pathway plays a critical role in proliferation, cell cycle, apoptosis and differentiation, and is an important downstream pathway of angiogenesis. 46 Previous data obtained in in vitro cultured cells showed that the Notch pathway upregulates the levels of ERK phosphorylation and GSI treatment could decrease p-ERK which presented therapeutic potential of targeting γ-secretase in non-small cell lung carcinoma. 28 And p-ERK also can be suppresses by CDDP alone and then inhibit cell proliferation. 45 In the present study, it was also found that p-ERK protein expression was downregulated by treatment with DAPT and CDDP alone or in combination.
So, it could be that CDDP plus DAPT inhibited the Notch, PI3K/ AKT, and MEK/ERK pathway, which induced the cell apoptosis and cell cycle arrest and inhibited cellular motility, and then leaded to tumor arrest ( Figure 7A ). are involved in the maintenance of stem cells. 22, 48 . Notch-activated mutation acted as a second hit in a p53-loss-driven OS model. 49 Mu et al 50 noted that Notch signaling may influence OSCs via suppression of ALDH and inhibited the Notch signaling pathway could reduce the OSCs properties. In this study, we also found that DAPT, Notch signaling pathway specific inhibitor, could reduce the number and volume of primary and secondary sphere assay. In addition, we used recombinant lentiviral specific blocking Notch1 signaling pathway, compared with the control group, it was found that: (1) the stem cell related gene expression was significantly decreased; and (2) the ability 
